A meta-analysis of five breast cancer TMA cohorts has previously indicated that FKBPL is an independent marker of good prognosis in breast cancer,19 not surprising given its anti-angiogenic and anti-CSC activity in this setting.19,21,23 Here we have demonstrated that the FKBPL peptide mimetic, ALM201, has antitumour activity in HGSOC and therefore postulated that FKBPL might also be a prognostic marker in this setting. This evidence concerns the gene FKBPL and breast cancer.